Moderna, Inc. (MRNA) – COVID 19 vaccine leading the performance

in , on June 25, 2021

Outside of vaccines, the company have seven clinical proof of concept trials ongoing across four modalities. Its VEGF program partnered with AstraZeneca is enrolling in a Phase 2.

Highlights

Valuation

– Enterprise Value
– CrispIdea Forecast
– Peer Valuation
– CrispIdea Forecast Relative to Consensus
– Consensus History and Surprise
– Consensus Momentum

Actual & Historical Performance

– Income Statement
– Balance Sheet
– Cash Flow
– 10 Year Historical Performance
– Ratio Analysis
– Segment Performance
– Key Metrics
– M&A Deals

Peer Performance

– Summary
– Profitability
– Growth
– Price Performance

Ownership

Stock Price Performance

Crispidea Coverage

No of Pages : 28

Release Information

  • Price
    :

    $99.00

  • Released
    :

    June 25, 2021

  • Last Updated
    :

    June 29, 2021